2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
|
EQS-News: Cannovum Cannabis AG
/ Key word(s): Forecast/Expansion
Cannovum Cannabis AG: April 2024 starts the legalization of cannabis in Germany, enormous potential for sales and growth
Cannovum Cannabis AG (stock exchanges Frankfurt/Xetra, Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A37FUP2) welcomes the upcoming legalization of cannabis and considers itself well positioned. According to consistent media reports in ZEIT, dpa and Berliner Morgenpost, the governing coalition of SPD, Greens and FDP has agreed on details for the legalization of cannabis. The law is to come into force on April 1.
The forthcoming law allows both the cultivation of recreational cannabis by private individuals and cultivation by cannabis clubs in Germany. Cannovum Cannabis AG holds a majority stake in the company Anbau-Allianz für Deutschland GmbH, in which leading German family-owned agricultural companies are organized.
"With our partners, we enable cannabis clubs to find optimal areas and other services for their cultivation in many regions of Germany. This is complemented by the capital and many years of expertise of our partners," says Klaus Madzia, CEO of Cannabis Cannabis AG. The Cultivation Alliance for Germany GmbH includes Osnabrück University of Applied Sciences, Hortensien Spieker, UN Moorman, Spex AI, Blumen Rieke, Gartenbauversicherung Deutschland VVaG, the international analytics company Wessling, the market leader for biological plant protection Koppert, Cox Gartenbau and the pot supplier Pottburri.
The growth and sales potential of legalization for Cannovum Cannabis AG is enormous. "According to our calculations, a single club in Germany can generate up to 2.4 million euros per year with cannabis. We expect there to be several thousand clubs in Germany in the medium term," says Klaus Madzia.
The current version of the forthcoming law also provides for comprehensive amendments to the Narcotics Act (BtMG), criminal law, pharmaceutical law and road traffic law. Due to the deletion of cannabis and THC from the BtMG, a restructuring of medical cannabis law is necessary. Experts expect a significant increase in demand due to the easier prescription practice by doctors. With its investment in Cannovum Health eG, Cannovum Cannabis AG is also benefiting from the imminent growth in the medical cannabis sector. Statista estimates the market potential in this area at more than 360 million euros for the year 2024.
Further information can be found at: www.cannovum.de
Contact:
Klaus Madzia
Board of Directors
Cannovum Cannabis AG
Phone +49 178 5811701 klaus.madzia@cannovum.com
About Cannovum Cannabis AG:
Cannovum AG (www.cannovum.de, www.cannovum.com) is the first fully licensed German cannabis company to be listed on the stock exchange. The shares are traded on the Frankfurt/Xetra, Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Cannovum Cannabis AG is ready and well prepared for the legalization of cannabis.
02.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Cannovum Cannabis AG |
| Stresemannstrasse 23 | |
| 10963 Berlin | |
| Germany | |
| Phone: | +49 (0)30 3982 16360 |
| E-mail: | klaus.madzia@cannovum.com |
| Internet: | www.cannovum.com |
| ISIN: | DE000A2LQU21 |
| WKN: | A2LQU2 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt, Hamburg, Munich, Tradegate Exchange |
| EQS News ID: | 1829187 |
| End of News | EQS News Service |
|
|
1829187 02.02.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
